Palisade Asset Management LLC Has $8.02 Million Position in Becton, Dickinson and Company $BDX

Palisade Asset Management LLC lowered its position in Becton, Dickinson and Company (NYSE:BDX) by 19.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 41,308 shares of the medical instruments supplier’s stock after selling 10,268 shares during the quarter. Palisade Asset Management LLC’s holdings in Becton, Dickinson and Company were worth $8,017,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC lifted its stake in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after buying an additional 877 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Becton, Dickinson and Company by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 32,455,790 shares of the medical instruments supplier’s stock worth $6,074,750,000 after buying an additional 147,041 shares during the last quarter. Skba Capital Management LLC lifted its stake in shares of Becton, Dickinson and Company by 1,619.9% during the 3rd quarter. Skba Capital Management LLC now owns 57,514 shares of the medical instruments supplier’s stock worth $10,765,000 after buying an additional 54,170 shares during the last quarter. Graybill Wealth Management LTD. lifted its stake in shares of Becton, Dickinson and Company by 47.3% during the 3rd quarter. Graybill Wealth Management LTD. now owns 27,592 shares of the medical instruments supplier’s stock worth $5,164,000 after buying an additional 8,859 shares during the last quarter. Finally, Danske Bank A S acquired a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth about $34,596,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock opened at $146.13 on Monday. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. The company has a 50-day simple moving average of $150.00 and a two-hundred day simple moving average of $173.93. The stock has a market capitalization of $40.27 billion, a price-to-earnings ratio of 37.00, a price-to-earnings-growth ratio of 10.35 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The business had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.67 billion. During the same quarter in the previous year, the company earned $3.35 EPS. The business’s revenue was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Analysts forecast that Becton, Dickinson and Company will post 12.61 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be issued a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 106.33%.

Insider Activity

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction dated Wednesday, June 10th. The shares were sold at an average price of $151.48, for a total value of $166,628.00. Following the transaction, the executive vice president directly owned 14,272 shares of the company’s stock, valued at $2,161,922.56. This trade represents a 7.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the firm’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 4,013 shares of company stock worth $593,434. Insiders own 0.40% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on BDX. The Goldman Sachs Group cut their target price on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a research note on Wednesday, May 27th. Wells Fargo & Company lifted their price objective on shares of Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a research note on Friday, May 8th. Stifel Nicolaus dropped their price objective on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a research note on Thursday, May 7th. Evercore lifted their price objective on shares of Becton, Dickinson and Company from $180.00 to $190.00 in a research note on Thursday, May 7th. Finally, Zacks Research upgraded shares of Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. Seven analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $182.73.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.